← Back to patent-cliff list
Fosmanogepix
Tier C — Watch / tradeFosmanogepix
Eisai Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Phosphatidylinositol-glycan biosynthesis class W protein
Indications (approved)：Candidaemia, 侵袭性真菌感染, 侵袭性念珠菌病, Candidiasis, Hepatic function decline, Fungal infection, Acute myeloid leukaemia
Regional status
US
Phase III
2024-12-12
EU
Phase III
2024-12-12
China
Phase III
2026-04-04
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fosmanogepix?
Approved indications include: Candidaemia, 侵袭性真菌感染, 侵袭性念珠菌病, Candidiasis, Hepatic function decline, Fungal infection, Acute myeloid leukaemia.
When does the Fosmanogepix patent expire?
No public expiry year is available for Fosmanogepix yet; this page updates once verified.
How do I get a quote for Fosmanogepix intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01